Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

Saved in:
Bibliographic Details
Title: Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
Authors: Burm R; Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Maravelia P; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Ahlen G; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Ciesek S; Institute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.; German Center for Infection Research, DZIF, External partner site, Frankfurt am Main, Germany., Caro Perez N; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Pasetto A; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany., Van Houtte F; Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Verhoye L; Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Wedemeyer H; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany., Johansson M; School of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, Orebro, Sweden., Frelin L; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden., Sällberg M; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden philip.meuleman@ugent.be matti.sallberg@ki.se., Meuleman P; Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium philip.meuleman@ugent.be matti.sallberg@ki.se.
Source: Gut [Gut] 2023 Jun; Vol. 72 (6), pp. 1186-1195. Date of Electronic Publication: 2022 Aug 17.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3288 (Electronic) Linking ISSN: 00175749 NLM ISO Abbreviation: Gut Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1468-3288
DOI:10.1136/gutjnl-2022-327216